Cardiac function of children with Duchenne muscular dystrophy
Sadek, A., Mahmoud, S., Abd alhalim, W. (2017). Cardiac function of children with Duchenne muscular dystrophy. EKB Journal Management System, 21(1), 273-280. doi: 10.21608/smj.2017.40782
Abdelrahim Sadek; Shaimaa Mahmoud; Walaa Abd alhalim. "Cardiac function of children with Duchenne muscular dystrophy". EKB Journal Management System, 21, 1, 2017, 273-280. doi: 10.21608/smj.2017.40782
Sadek, A., Mahmoud, S., Abd alhalim, W. (2017). 'Cardiac function of children with Duchenne muscular dystrophy', EKB Journal Management System, 21(1), pp. 273-280. doi: 10.21608/smj.2017.40782
Sadek, A., Mahmoud, S., Abd alhalim, W. Cardiac function of children with Duchenne muscular dystrophy. EKB Journal Management System, 2017; 21(1): 273-280. doi: 10.21608/smj.2017.40782

Cardiac function of children with Duchenne muscular dystrophy

Sohag Medical Journal
Article 28, Volume 21, Issue 1, January 2017, Page 273-280  XML PDF (79.48 K)
Document Type: Original Article
DOI: 10.21608/smj.2017.40782
View on SCiNiTO View on SCiNiTO
Authors
Abdelrahim Sadekorcid ; Shaimaa Mahmoud; Walaa Abd alhalim
Department of Pediatrics ,Faculty of Medicine, Sohag University, Sohag, Egypt.
Abstract
Background:Duchenne muscular dystrophy (DMD) is the most common childhood form of muscular dystrophy. Clinical guidelines recommend that
evaluations for cardiomyopathy, arrhythmia, and heart failure be performed
upon diagnosisThe incidence of cardiomyopathy in DMD increases with age Early detection of muscular dystrophy associated cardiomyopathy is
important, because institution of cardioprotective medical therapies may slow
adverse remodeling and attenuate heart failure symptoms in these patients.
Aim: evaluation of cardiac function in children clinically suspected to have Duchenne muscular dystrophy.
Methods:28 male children who met criteria for diagnosis of Duchenne muscular dystrophy aged from 3 to 18 years compared to 47 healthy control children were approached to participate in the study and, after consent, were submitted to full clinical examination, blood samples were collected to determinate CPK (creatinine phosphokinase), Troponin I enzyme, Myoglobin and LDH (lactate dehydrogenase) enzyme level,echocardiography and 12-lead electrocardiogram were done.
Results:
28 Duchenne muscular dystrophy children and 47 age matched healthy male control children were included in the study. The mean age of study group was 7.29±3.24 years, and the mean age of the control group was 8.06±2. 86 years (p value 0 .28). 25% of cases had Positive family history of DMD. 35.7% of cases had positive consanguinity.all our  cases had elevated CPK  level (creatine phosphokinase)   .The mean  CPK level of cases  was 2495.79 ± 3457.02  While CPK level in controls was normal, (p value<0.0001). LDH level was elevated in 19 cases 67.86% of cases. The mean serum LDH level in DMD cases was 1232.07 ± 617.72. All control children have normal LDH level with mean 163.02 ± 109.62, (P value : <0.0001).The mean serum myoglobin level of (DMD) patients was higher relative to that of healthy controls   (but still within normal limits) 39.39  ± 7.25 versus 33.68 ±12.38 (ng/ml) respectively with statistically significant difference (P value: 0.01).There was no statistically significant difference between mean serum troponin I   level of DMD patients and that of controls 0 .03 ± 0.05 versus 0.01 ±0 .02  (U/L) respectively (p value: 0.37). Echocardiography of our patients revealed that one patient (3.57%)   had mild dilation of the left ventricular cavity which was statistically not significant, (P value: 0.37).7 cases (25%) of patients had low Ejection fraction (EF) and fraction shortening (FS) with mean (EF) 59.86 ± 10.20. All control children have normal EF with mean 73.30 ± 5.08 (P value : <0.0001). The mean FS was 20.29±5.59. All control children had normal (FS) with mean ±SD 36.17± 2.58 (P value : <0.0001). Electrocardiogram showed 28.57% of cases had sinus tachycardia with average heart rate (HR) 107 ±12.32 136. While 6.88% of controls had sinus tachycardia; (P value: 0.0001). Prolonged QTc interval was present  in39.29% of cases with a  mean of 431.39 ± 43.60 and that of controls was 415.17±25.2 (p value : <0.0001).  QTc duration of controls were normal for age. Other parameters of ECG were normal for age; no type of arrhythmia could be detected apart from sinus tachycardia.
Conclusion:ECG manifestations in children with DMD in the form of sinus tachycardia and prolonged QTC interval are an early alarm for developing cardiomyopathy before overt echocardiographic findings appear
Keywords
Duchenne muscular dystrophy; Echocardiography; electrocardiography; Cardiac
Supplementary Files
References
  1. Tuffery-Giraud S, Beroud C, Leturcq F, et al.; Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat; 30 (6): 934–45, 2009.
  2. Boland BJ, Silbert PL, Groover RV, et al.: Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy. PediatrNeurol ;14 (1):7-12, 1996 .
  3. Bushby K, Muntoni F, Bourke JP.: 107th ENMC International Workshop: The Management of Cardiac Involvement in Muscular Dystrophy and Myotonic Dystrophy, 7th–9th June 2002, Naarden, the Netherlands. NeuromusculDisord; 13:166–172, 2003.
  4. Wagner KR, Lechtzin N, Judge DP.: Current treatment of adult Duchenne muscular dystrophy. BiochimBiophysActa; 1772 (2): 229-37, 2007.
  5. Kwon SW, Kang S, Kim J, et al.: Outcomes of cardiac involvement in patients with late-stage Duchenne  muscular dystrophy under management in the pulmonary rehabilitation center of a tertiary referral hospital. Cardiology. ; 121:186–93, 2012.
  6. Hampton JR. The ECG Made Easy. 7th edition. London: Churchill Livingstone 2008.
  7. Morris STW,Galiatsou E, Stewart GA,et al: QT dispersal before and after dialysis. J AmSocNephrol10:160–163, 1999.
  8. Galliatsou E, Morris S, Jardine AG, et al: Cardiovascular abnormalities in renal transplant patients: Differential effects of cyclosporine and azathioprine. J Nephrol13:185–192, 2000.
  9. R. Rijnbeek, M. Witsenburg, E. Schrama, J. Hess and J. A. Kors, Normal limits for the paediatricECG ,Eur Heart J, April 2001.
  10. Emery AEH. :Duchenne muscular dystrophy or Meryon’s disease. In:The Muscular Dystrophies. 2nd edition. Oxford: Oxford University Press, 55–71, 1993..
  11. Melacini P, Vianello A, Villanova C, et al.; Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy. Neuromuscular Disord ;6:367–376, 1996.
  12. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, et al.:   Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years’ follow-up. Am Heart J 154:596–602, 2007.
  13. Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, et al.: Genetic predictors and remodeling of dilated   cardiomyopathy in muscular dystrophy. Circulation  ;112   :2799–2804, 2005 .
  14. Kajimoto H, Ishigaki K, Okumura K, Tomimatsu H, Nakazawa   M, Saito K, et al.:  Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J ;70:991–994, 2006. 
  15. Ramaciotti C, Heistein LC, Coursey M, Lemler MS, Eapen RS, Iannaccone         ST, Scott WA.: Left ventricular function and response to enalapril in patients       with Duchenne muscular dystrophy during the second decade of life.Am J     Cardiol. ; 98:825–827, 2006.
  16. Gesmar Volga Haddad Herd, Roberta Duarte Bezerra Pinto Guilherme de Almeida Costa Ana FlaviaMalheirosTorbey, VivianneGalante Ramos., MarcioMoacyrVasconcelos., Clinical and Molecular Study on Duchenne Muscular  Dystrophy. internacional Journal of Cardiovascular Sciences. ;28(3):173-180, 2015.
  17. Ohlendieck, K. Proteomic identification of biomarkers of skeletal muscle disorders. Biomark Med; 7(1): 169-186, 2013.
  18. Carp, S. J., Barr, A. E., and Barbe, M. F., : Serum biomarkers assignals  for risk and severity of work-related musculoskeletal injury. Biomark      Med.; 2(1): 67-79, 2008.
  19. Brancaccio, P., Lippi, G., and Maffulli, N., :  Biochemical markers of muscular damage. ClinChem Lab Med;48(6): 757-767,  2010.
  20. Hathout, Y., Brody, E., Clemens, P. R., Cripe, L., DeLisle, R. K., Furlong, P.,Gold L.: Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy.Proceedings of the National Academy of Sciences of the United States of America, 112(23), 7153–7158, 2015.
  21. Markham   LW,   Michelfelder   EC,   Border   1WL,   Khoury     PR,   SpicerRL, Wong   BL, et al. Abnormalities   of diastolic  function   precede    dilated cardiomyopathy  associated  with  Duchenne  muscular  dystrophy. J Am   SocEchocardiogr  ;19:865–871, 2006.
  22. Philip T., Thrush, Hugh D. Allen , Laurence Viollet,Jerry R. Mendell :.Re-examination of the Electrocardiogram in Boys With Duchenne Muscular Dystrophy and Correlation With Its Dilated Cardiomyopathy.The American    Journal of Cardiology Volume 103, Issue 2,  Pages 262–265, 2009. 
  23. Tamara O. Thomas ,Thomas M, Morgan William, B. Burnette ,Larry W.;  Markham. Correlation of Heart Rate and Cardiac Dysfunction in Duchenne Muscular Dystrophy .pediatrCardiol ;33:1175–1179, 2012 .
  24. Spurney, Christopher F. :Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions." Muscle &nerve ;44.1: 8-19, 2011.
  25. Martin AB, Garson A Jr, Perry JC. Prolonged QT interval in hypertrophic and dilated cardiomyopathy in children. Am Heart J. 1994 Jan;127(1):64-70.
Statistics
Article View: 173
PDF Download: 214